Off-label prescribing of GLP-1 diabetes drugs for weight loss created supply shortages that made it harder for diabetes patients to access their medications.
Prior authorization now requiredInsurance companies began requiring proof of diabetes diagnosis before covering GLP-1 drugs due to off-label weight loss demand
What the researchers found
Semaglutide outperformed dulaglutide in both HbA1c reduction and weight loss, making it the most sought-after GLP-1 drug. Clinicians began prescribing Ozempic (semaglutide for diabetes) off-label for weight loss, even though Wegovy (semaglutide for weight) existed. This drove shortages.
Insurance companies responded by requiring prior authorizations proving a type 2 diabetes diagnosis before covering these drugs. The commentary notes that most insurance plans still do not cover GLP-1 drugs solely for weight management, pushing weight-loss demand onto the diabetes supply chain.
Why it matters
GLP-1 drugs are among the most effective diabetes treatments available. When people with diabetes cannot access them because of demand from weight-loss prescribing, it creates a real clinical problem. This tension between obesity treatment and diabetes management has become one of the biggest access issues in modern medicine.
The numbers in context
- Semaglutide: FDA-approved for diabetes (Ozempic) and weight loss (Wegovy)
- Dulaglutide: outperformed by semaglutide in HbA1c and weight reduction
- Tirzepatide: FDA-approved for diabetes May 2022
- Insurance now requires prior authorization proving T2DM diagnosis
How the study worked
This is a clinical commentary based on published literature and clinical experience. It describes prescribing trends, FDA approval timelines, and insurance coverage issues for dulaglutide, semaglutide, and tirzepatide. No original data analysis was performed.
Who was studied
General discussion of diabetes patients and GLP-1 drug access in the US healthcare system
What this study cannot tell us
This is a brief commentary, not a systematic study. It does not quantify the extent of shortages or measure patient outcomes from delayed access. The perspectives are from US clinical practice and may not apply globally. The timeline described (2022-2023) is now partially outdated as supply has improved in some areas.
How to read the evidence
Rated preliminary: this is a clinical commentary based on prescribing trends and clinical experience, not a data-driven study.
When this study was published
Published in 2024, describing events from 2022–2023. Supply situations have evolved since publication.
The bigger picture
The tension between obesity treatment and diabetes medication access has become one of the biggest pharmaceutical access issues in modern medicine, affecting millions of patients worldwide.
Questions still open
- Will increased production capacity resolve the shortage?
- Should separate supply chains exist for diabetes vs weight loss prescriptions?
Common questions
Why is it hard to get Ozempic?
What is the difference between Ozempic and Wegovy?
Read the original research
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
Clinical therapeutics, 46(3), 289-292
Citation
Powell, Jason; Taylor, James. (2024). Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.. Clinical therapeutics, 46(3), 289-292. https://doi.org/10.1016/j.clinthera.2023.12.014